|
1
|
Raymond AK, Chawla SP, Carrasco CH, Ayala
AG, Fanning CV, Grice B, Armen T, Plager C, Papadopoulos NE,
Edeiken J, et al: Osteosarcoma chemotherapy effect: A prognostic
factor. Semin Diagn Pathol. 4:212–236. 1987.PubMed/NCBI
|
|
2
|
Rosen G, Caparros B, Huvos AG, Kosloff C,
Nirenberg A, Cacavio A, Marcove RC, Lane JM, Mehta B and Urban C:
Preoperative chemotherapy for osteogenic sarcoma: Selection of
postoperative adjuvant chemotherapy based on the response of the
primary tumor to preoperative chemotherapy. Cancer. 49:1221–1230.
1982. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Robak M, Treliński J and Chojnowski K:
Hemostatic changes after 1 month of thalidomide and dexamethasone
therapy in patients with multiple myeloma. Med Oncol. 29:3574–3580.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chen Q, Lin RB, Ye YB, Fan NF, Guo ZQ,
Zhou ZF, Wang XJ, Chen MS, Chen SP and Li JY: The combined
administration of partially HLA-matched irradiated allogeneic
lymphocytes and thalidomide in advanced renal-cell carcinoma: A
case report. Med Oncol. 27:554–558. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rezvani H, Haghighi S, Ghadyani M and
Attarian H: Efficacy of taxotere, thalidomide, and prednisolone in
patients with hormone-resistant metastatic prostate cancer. Urol J.
9:673–677. 2012.PubMed/NCBI
|
|
6
|
Lv J, Liu N, Liu KW, Ding AP, Wang H and
Qiu WS: A randomised controlled phase II trial of the combination
of XELOX with thalidomide for the first-line treatment of
metastatic colorectal cancer. Cancer Biol Med. 9:111–114.
2012.PubMed/NCBI
|
|
7
|
Lee SM and Hackshaw A: A potential new
enriching trial design for selecting non-small-cell lung cancer
patients with no predictive biomarker for trials based on both
histology and early tumor response: Further analysis of a
thalidomide trial. Cancer Med. 2:360–366. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
de Souza CM, Araújoe Silva AC, de Jesus
Ferraciolli C, Moreira GV, Campos LC, dos Reis DC, Lopes MT,
Ferreira MA, Andrade SP and Cassali GD: Combination therapy with
carboplatin and thalidomide suppresses tumor growth and metastasis
in 4T1 murine breast cancer model. Biomed Pharmacother. 68:51–57.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tunio MA, Hashmi A, Qayyum A, Naimatullah
N and Masood R: Low-dose thalidomide in patients with metastatic
renal cell carcinoma. J Pak Med Assoc. 62:876–879. 2012.PubMed/NCBI
|
|
10
|
Tsai YC, Wu CT and Hong RL: Response of
refractory osteosarcoma to thalidomide and celecoxib. Lancet Oncol.
6:997–999. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zu C, Zhang M, Xue H, Cai X, Zhao L, He A,
Qin G, Yang C and Zheng X: Emodin induces apoptosis of human breast
cancer cells by modulating the expression of apoptosis-related
genes. Oncol Lett. 10:2919–2924. 2015.PubMed/NCBI
|
|
12
|
Huang W, Liu J, Feng X, Chen H, Zeng L,
Huang G, Liu W, Wang L, Jia W, Chen J, et al: DLC-1 induces
mitochondrial apoptosis and epithelial mesenchymal transition
arrest in nasopharyngeal carcinoma by targeting EGFR/Akt/NF-κB
pathway. Med Oncol. 32:1152015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu X, Yue P, Zhou Z, Khuri FR and Sun SY:
Death receptor regulation and celecoxib-induced apoptosis in human
lung cancer cells. J Natl Cancer Inst. 96:1769–1780. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cory S, Huang DC and Adams JM: The Bcl-2
family: Roles in cell survival and oncogenesis. Oncogene.
22:8590–8607. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang M, Zhang P, Zhang C, Sun J, Wang L,
Li J, Tian Z and Chen W: Prognostic significance of Bcl-2 and Bax
protein expression in the patients with oral squamous cell
carcinoma. J Oral Pathol Med. 38:307–313. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Faggiano A, Sabourin JC, Ducreux M,
Lumbroso J, Duvillard P, Leboulleux S, Dromain C, Colao A,
Schlumberger M and Baudin E: Pulmonary and extrapulmonary poorly
differentiated large cell neuroendocrine carcinomas: Diagnostic and
prognostic features. Cancer. 110:265–274. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Salvesen GS and Dixit VM: Caspases:
Intracellular signaling by proteolysis. Cell. 91:443–446. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Thornberry NA and Lazebnik Y: Caspases:
Enemies within. Science. 281:1312–1316. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Aggarwal BB and Shishodia S: Molecular
targets of dietary agents for prevention and therapy of cancer.
Biochem Pharmacol. 71:1397–1421. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lu T, Sathe SS, Swiatkowski SM, Hampole CV
and Stark GR: Secretion of cytokines and growth factors as a
general cause of constitutive NFkappaB activation in cancer.
Oncogene. 23:2138–2145. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lu T and Stark GR: Cytokine overexpression
and constitutive NFkappaB in cancer. Cell Cycle. 3:1114–1117. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Okayasu I, Ohkusa T, Kajiura K, Kanno J
and Sakamoto S: Promotion of colorectal neoplasia in experimental
murine ulcerative colitis. Gut. 39:87–92. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Greten FR, Eckmann L, Greten TF, Park JM,
Li ZW, Egan LJ, Kagnoff MF and Karin M: IKKbeta links inflammation
and tumorigenesis in a mouse model of colitis-associated cancer.
Cell. 118:285–296. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
DiDonato JA, Mercurio F and Karin M: NF-κB
and the link between inflammation and cancer. Immunol Rev.
246:379–400. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kashani-Sabet M, Shaikh L, Miller JR III,
Nosrati M, Ferreira CM, Debs RJ and Sagebiel RW: NF-κB in the
vascular progression of melanoma. J Clin Oncol. 22:617–623. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Karin M: Nuclear factor-kappaB in cancer
development and progression. Nature. 441:431–436. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
He H, Ni J and Huang J: Molecular
mechanisms of chemoresistance in osteosarcoma (Review). Oncol Lett.
7:1352–1362. 2014.PubMed/NCBI
|
|
28
|
Ek ET and Choong PF: The role of high-dose
therapy and autologous stem cell transplantation for pediatric bone
and soft tissue sarcomas. Expert Rev Anticancer Ther. 6:225–237.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yang C, Hornicek FJ, Wood KB, Schwab JH,
Mankin H and Duan Z: RAIDD expression is impaired in multidrug
resistant osteosarcoma cell lines. Cancer Chemother Pharmacol.
64:607–614. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Scheele C, Nielsen S and Pedersen BK: ROS
and myokines promote muscle adaptation to exercise. Trends
Endocrinol Metab. 20:95–99. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Franks ME, Macpherson GR and Figg WD:
Thalidomide. Lancet. 363:1802–1811. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li M, Kondo T, Zhao QL, Li FJ, Tanabe K,
Arai Y, Zhou ZC and Kasuya M: Apoptosis induced by cadmium in human
lymphoma U937 cells through Ca2+-calpain and
caspase-mitochondria- dependent pathways. J Biol Chem.
275:39702–39709. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Mohamad N, Gutiérrez A, Núñez M, Cocca C,
Martín G, Cricco G, Medina V, Rivera E and Bergoc R: Mitochondrial
apoptotic pathways. Biocell. 29:149–161. 2005.PubMed/NCBI
|
|
34
|
Orrenius S, Gogvadze V and Zhivotovsky B:
Mitochondrial oxidative stress: Implications for cell death. Annu
Rev Pharmacol Toxicol. 47:143–183. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yin XM: Signal transduction mediated by
Bid, a pro-death Bcl-2 family proteins, connects the death receptor
and mitochondria apoptosis pathways. Cell Res. 10:161–167. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ermak G and Davies KJ: Calcium and
oxidative stress: From cell signaling to cell death. Mol Immunol.
38:713–721. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Pan JS, Hong MZ and Ren JL: Reactive
oxygen species: A double-edged sword in oncogenesis. World J
Gastroenterol. 15:1702–1707. 2009. View Article : Google Scholar : PubMed/NCBI
|
